Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Cerilliant
Healthtrust
Colorcon
Julphar
AstraZeneca
Farmers Insurance
Chubb
Daiichi Sankyo

Generated: October 19, 2017

DrugPatentWatch Database Preview

Cysteamine bitartrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cysteamine bitartrate and what is the scope of cysteamine bitartrate freedom to operate?

Cysteamine bitartrate
is the generic ingredient in two branded drugs marketed by Horizon Pharma Usa and Mylan, and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cysteamine bitartrate has thirty-six patent family members in twenty-five countries and six supplementary protection certificates in five countries.

There are five drug master file entries for cysteamine bitartrate. Two suppliers are listed for this compound.

Summary for Generic Name: cysteamine bitartrate

US Patents:5
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: see list5
Suppliers / Packagers: see list2
Bulk Api Vendors: see list14
Clinical Trials: see list54
Patent Applications: see list110
Therapeutic Class:Enzyme Replacements/Modifiers
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:cysteamine bitartrate at DailyMed

Pharmacology for Ingredient: cysteamine bitartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan
CYSTAGON
cysteamine bitartrate
CAPSULE;ORAL020392-002Aug 15, 1994RXYesYes► Subscribe► Subscribe► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: cysteamine bitartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,129,433Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
9,750,708Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
9,511,039Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cysteamine bitartrate

Country Document Number Estimated Expiration
Australia2014281702► Subscribe
European Patent Office2535044► Subscribe
Portugal1919458► Subscribe
World Intellectual Property Organization (WIPO)2014204881► Subscribe
European Patent Office3010491► Subscribe
Argentina096628► Subscribe
Taiwan201534357► Subscribe
Japan2016523250► Subscribe
Mexico2015017366► Subscribe
Netherlands300649► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CYSTEAMINE BITARTRATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4 50001-2014Slovakia► SubscribePRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906
0649Netherlands► SubscribePRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
/2014Austria► SubscribePRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
2014 00013Denmark► SubscribePRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906
2014000023Germany► SubscribePRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906
00649Netherlands► SubscribePRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
US Department of Justice
Julphar
US Army
Novartis
Healthtrust
Johnson and Johnson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot